Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2016)

Soleno Therapeutics (SLNO) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $13.0 as the latest value for Q4 2016.

  • For Q4 2016, Preferred Stock Liabilities rose 160.0% year-over-year to $13.0; the TTM value through Dec 2016 reached $13.0, up 160.0%, while the annual FY2016 figure was $13.0, 160.0% up from the prior year.
  • Preferred Stock Liabilities hit $13.0 in Q4 2016 for Soleno Therapeutics, up from $5.0 in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $6.9 million in Q3 2014 and bottomed at $5.0 in Q4 2015.
  • Average Preferred Stock Liabilities over 4 years is $3.4 million, with a median of $3.4 million recorded in 2013.
  • On a YoY basis, Preferred Stock Liabilities climbed as much as 160.0% in 2016 and fell as far as 160.0% in 2016.
  • Soleno Therapeutics' Preferred Stock Liabilities stood at $6.9 million in 2013, then increased by 0.0% to $6.9 million in 2014, then crashed by 100.0% to $5.0 in 2015, then soared by 160.0% to $13.0 in 2016.
  • According to Business Quant data, Preferred Stock Liabilities over the past three periods came in at $13.0, $5.0, and $6.9 million for Q4 2016, Q4 2015, and Q3 2014 respectively.